摘要世界卫生组织（WHO）有关造血与淋巴组织肿瘤的国际诊断和分类标准（WHO-HEAM）自2001年以来，经历了多个版本的升级和修订，对先前一些肿瘤的诊断和分类标准进行了更新、澄清和细化，同时增加了许多新的遗传学和分子生物学亚型。由于大量临床和科学研究结果的出现以及专家对诊断分类的分歧，2022年出现了两个分类建议，即2022年Leukemia杂志上发布的第5版WHO造血与淋巴组织分类（WHO-HAEM5）和Blood杂志上发表的国际共识分类（ICC）。这两个方案对造血与淋巴组织肿瘤的分类有所不同，给临床实验室诊断和治疗带来了一些困扰和挑战。

abstractsThe World Health Organization (WHO) classification serves as the internationally recognized standard for diagnosing and classifying hematopoietic and lymphoid tissue tumors(WHO-HEAM). Since 2001, it has undergone multiple upgrades and revisions, updating, clarifying, and refining previous tumor diagnostic and classification standards while incorporating numerous new genetic and molecular biological subtypes. In 2022, two classification proposals emerged due to a wealth of clinical and scientific research results: the fifth edition of the WHO hematopoietic and lymphoid tissue classification (WHO-HAEM5), published in Leukemia journal; and the International Consensus Classification (ICC), published in Blood journal. These two schemes differ in their approach to classifying hematopoietic and lymphoid tissue tumors, posing challenges for clinical laboratory diagnosis and treatment.